Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (197)	4/23/2005 2:42:57 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

From an interview with Tartaglia "finding new indications for failed compounds" "rescuing failed compounds" "expand the market of live drugs" "look at very advanced clinical compounds" "the application of toxicogenomics" Partly because the formatting was wrecked I have not pasted the document--so go here: It is the second hit, while it lasts... google.com Skip way down past the article about glgc for the interview with Tartaglia. He mentions some interesting stuff like mouse imagining experiments and genetic ADME. If you get excited, read the third hit off of google this morning--a newspaper article with scathing comments from a Brendan Bogart...an investor with Mel Capital in Emerson, N.J. gazette.net

To: Steve Lokness who wrote (197)	4/24/2005 5:31:20 PM
From: keokalani'nui	Respond to of 360

Steve, In a human genetic association study, dcgn first identified a pathway common in an Icelandic population which confers a higer risk of MI (as well elevated, important surrogates like crp and mpo). The comany also confirmed their premise that the leukotrienne pathway is imporatnt to MI in a small UK population (i don't recall if this was with the compound, or whether it was an association study as well) study. So it is not a subpopulation like an enzyme replacement subpopulation. It has been discovered in a subpopulation, but it includes such a substantial portion of humans that practically speaking it is the market. Here's what you are missing. The Bayer cpd that will go into P3 this year has had substantial safety studies in humans, but was dropped because of efficacy for the indication. I believe there ahve been long term, multi-dose human studies already booked for dcg-031, by Bayer. Bayer may just be kicking themselves in the head if dcg-031 works for MI because I think they only have a modest royalty back. I imagine glgc's customers hope not to look like Bayer someday.